Results 161 to 170 of about 4,142,440 (303)

Estimating thresholds for risk of cannabis use disorder using standard delta‐9‐tetrahydrocannabinol (THC) units

Addiction, EarlyView.
Abstract Background and aims Lower risk guidelines for safer levels of cannabis use could help to reduce the health burden posed by cannabis use disorder (CUD). We aimed to estimate risk thresholds for CUD based on delta‐9‐tetrahydrocannabinol (THC) consumption using standard THC units (1 unit = 5 mg THC).
Rachel Lees Thorne, Will Lawn, Kat Petrilli, Katie Trinci, Anya Borissova, Shelan Ofori, Claire Mokrysz, H. Valerie Curran, Lindsey A. Hines, Tom P. Freeman   +9 more
wiley   +1 more source

Impact of Medical Marijuana Laws on State-Level Marijuana Use by Age and Gender, 2004–2013

Prevention Science, 2019
Christine M Mauro, Paul Newswanger, Julián Santaella-Tenorio, P. Mauro, Hannah Carliner, S. Martins   +5 more
semanticscholar   +1 more source

Associations between county‐level e‐cigarette‐inclusive Tobacco 21 law population coverage and e‐cigarette use behaviors among United States adolescents in Monitoring the Future

Addiction, EarlyView.
Abstract Background and aims In the United States (US), Tobacco 21 (T21) laws set the minimum legal sale age for all tobacco products to 21 years. This study aimed to examine whether e‐cigarette‐inclusive T21 laws were associated with e‐cigarette use behaviors and related disparities among US adolescents.
James H. Buszkiewicz, Catherine A. Vander Woude, Yanmei Xie, Steven Cook, Bukola Usidame Peters, Megan E. Patrick, Michael R. Elliott, James F. Thrasher, Nancy L. Fleischer   +8 more
wiley   +1 more source

Medical marijuana utilization in gynecologic cancer patients. [PDF]

Gynecol Oncol Rep, 2021
Fehniger J, Brodsky AL, Kim A, Pothuri B.   +3 more
europepmc   +1 more source

Development of a novel risk score reflecting the relative harm potential of synthetic cannabinoids based on prevalence estimates, well‐documented intoxication cases and basic pharmacological data

Addiction, EarlyView.
Abstract Background and aims While the health hazards of synthetic cannabinoid receptor agonists (SCRAs) are often approximated using in vitro pharmacological parameters as surrogate, this approach fails to consider pharmacokinetic and pharmacodynamic complexity.
Michaela J. Sommer, Katharina Elisabeth Grafinger, Maren Hermanns‐Clausen, Volker Auwärter   +3 more
wiley   +1 more source

Outdated tools, underestimated harm: Modernizing cannabis surveillance in a post‐legalization era

Addiction, EarlyView.
Abstract Background Canada's 2018 legalization of non‐medical cannabis was positioned as a public health initiative, intended to shift cannabis use from criminalization to regulation. Since then, cannabis access and consumption have grown significantly but the systems used to monitor cannabis‐related harms have not kept pace.
Anees Bahji
wiley   +1 more source

Medical Marijuana in the Mid-Atlantic Region. [PDF]

Dela J Public Health
Khan M, Agarwal V.
europepmc   +1 more source

Clinical Characteristics and Quality of Life in Adults Initiating Medical Marijuana Treatment. [PDF]

Med Cannabis Cannabinoids, 2022
Buonomano LS, Mitnick MM, McCalmont TR, Syracuse P, Dugosh KL, Festinger DS, Lent MR.   +6 more
europepmc   +1 more source

Deductions on a Higher Plane: Medical Marijuana Business Expenses [PDF]

, 2013
Joel S. Newman
openalex  

Medical marijuana for urologic chronic pelvic pain

, 2018
J. Curtis Nickel
openalex   +2 more sources